DIPHERELINE

This brand name is authorized in Australia, Ecuador, Estonia, Hong Kong, Lithuania, Poland, Romania, Singapore

Active ingredients

The drug DIPHERELINE contains one active pharmaceutical ingredient (API):

1 Triptorelin UNII 9081Y98W2V - TRIPTORELIN

Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotropins. Read about Triptorelin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DIPHERELINE Powder and solvent for suspension for injection	Pharmaceutical Benefits Scheme (AU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02AE04	Triptorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5297T, 9378N, 9379P
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 4972-MEE-0220, 5168-MEE-0620
Country: EE	Ravimiamet	Identifier(s): 1012868, 1040397, 1400421, 1818604, 1822968
Country: HK	Department of Health Drug Office	Identifier(s): 47655, 51941, 53473, 62788
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1002990, 1003523, 1005529, 1008105, 1086457, 1087838, 1091101
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100094400, 100103027, 100103719, 100242600
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W55725001, W55726002, W55727001, W62618001
Country: SG	Health Sciences Authority	Identifier(s): 14634P, 14635P